Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q2 2016 · 10-Q
Revenue$12.09M$12.09M−39.8% vs Q2 2015 Net Income-$35.06M-$35.06MN/M vs Q2 2015 EPS Diluted-$0.33-$0.33N/M vs Q2 2015 Operating Income-$33,893,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$32,296,000N/M Margins · derivedOperating margin-280.4%−96.1 pt vs Q2 2015
Net margin-290.1%−100.3 pt vs Q2 2015
ended Jun 30, 2017 · filed Aug 1, 2017 · 32 d after period end